SCHEMBL1353280

SCHEMBL1353280

COc1ccc(C(N)=O)cc1C(=O)Nc1cccc2ncccc12

nearest known ligand 0.74

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.74
KDM4E B2RXH2 2/20 0.74
L3MBTL1 Q9Y468 2/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
HSD17B10 Q99714 1/20 0.65
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57
POLB P06746 1/20 0.57
HDAC6 Q9UBN7 1/20 0.55
PABPC1 P11940 4/20 0.55
EIF4H Q15056 4/20 0.55
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CLK1 P49759 1/20 0.52
LMNA P02545 1/20 0.52
IRAK4 Q9NWZ3 1/20 0.52
MAPK1 P28482 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1351165 0.83 ALDH1A1 (0.64) MAPTKDM4ESMN1; SMN2HSD17B10MEN1
SCHEMBL1353113 0.79 RAB9A (0.64) MAPTL3MBTL1SMN1; SMN2HSD17B10MEN1
SCHEMBL1353420 0.77 KDM4E (0.56) MAPTKDM4EHSD17B10MEN1KMT2A
SCHEMBL1353162 0.77 PDE4D (0.57) MAPTKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL10353118 0.76 GAA (0.61) MAPTKDM4EL3MBTL1SMN1; SMN2HSD17B10
SCHEMBL1354395 0.76 PDE4D (0.70) MAPTKDM4EMEN1KMT2APOLB
SCHEMBL1351225 0.76 PDE4D (0.57) MAPTKDM4ESMN1; SMN2MEN1KMT2A
SCHEMBL1352789 0.76 CHEK1 (0.58) MAPTKDM4EHSD17B10MEN1KMT2A
SCHEMBL7502761 0.76 MEN1 (0.65) MAPTKDM4EL3MBTL1SMN1; SMN2HSD17B10
SCHEMBL19616383 0.76 HDAC6 (0.74) MAPTKDM4EL3MBTL1SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063046-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-22 US disclosed
US-8063046-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-22 US disclosed
US-8063046-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-22 US disclosed
EP-1698618-B1 BENZAMIDE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2011-05-18 EP disclosed
US-20100179326-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-15 US disclosed
US-20100179326-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-15 US disclosed
US-20100179326-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-07-15 US disclosed
US-7705053-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-04-27 US disclosed
US-7705053-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-04-27 US disclosed
US-7705053-B2 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-04-27 US disclosed
US-20070123493-A1 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-31 US disclosed
US-20070123493-A1 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-31 US disclosed
US-20070123493-A1 Benzamide derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-31 US disclosed
EP-1698618-A1 BENZAMIDE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123493-A1 Benzamide derivative BDKRB1, BDKRB2, NR1H2 MAPT 4772/4885KDM4E 2503/4885L3MBTL1 1513/4885
US-20100179326-A1 BENZAMIDE DERIVATIVE NR0B2, NR1H2, CNR2 MAPT 4799/4885KDM4E 2365/4885L3MBTL1 1036/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.